08.02.21
Ireland
www.perrigo.com
Sales: $926 million
Corporate sales: $5.0 billion.
Key Personnel
Rolf A. Classon, chairman; Murray S. Kessler, president and chief executive officer; Svend Andersen, EVP and president, Consumer Self-Care International; Richard S. Sorota, EVP and president, Consumer Self-Care Americas; James E. Dillard III, EXP and chief scientific officer; Grainne Quinn, EVP and chief medical officer; Ronald C. Janish, chief transformation officer
Major Products
Skin care, personal care and oral care products: ScarAway, Plackers, Rembrandt, Steripod, Firefly, Reach, Dr. Fresh, Aco, Biodermal, Canoderm, Dermalex, Lactacyd, Wartner, Jungle Formula, Paraniz, Pencivir
New Products
Steripod toothbrush accessories (acquisition), Emolium, Iwostin and Loxon skin care (acquisition).
Perrigo has acquired Steripod, which makes toothbrush protectors that guard toothbrushes from airborne contaminants, such as dirt, hair or debris, during travel and when staying home.
Comments: Perrigo, in its own words, is transforming into a pure-play “Consumer Self-Care Company,” and as such, spent much of 2020 expanding in that direction via acquisition and selling off operations outside that scope.
For example, in February 2020, Perrigo acquired the oral care assets of High Ridge Brands for $113 million in cash. In June 2020 it agreed to sell its UK-based Rosemont Pharmaceuticals business to a private equity firm.
Two months later, in August, it acquired three Eastern European OTC skin care and hair loss treatment brands (Emolium, Iwostin and Loxon) from Sanofi, which together generation sales of about $23 million a year.
The company continued to reshape its business in 2021. In May, it reached a definitive agreement to sell its Mexico and Brazil-based over-the-counter (OTC) businesses to Advent International. Last month, the company completed the sale of its generic Rx pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion.
“Closing this transaction was another important milestone for Perrigo’s transformation. We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality—to make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company’s future,” Perrigo CEO and President Murray S. Kessler, said when the Altaris deal was complete.
While legally based in Ireland, Perrigo building a new North American corporate headquarters in Grand Rapids, MI, specifically at Michigan State University’s Grand Rapids Innovation Park. The new HQ will augment its existing and storied presence in west Michigan, which was established in 1887 and currently includes operations in Allegan and Holland, too.
Like other personal care makers, Perrigo has some interest in CBD; it has formed a strategic investment in and long-term supply agreement with Kazmira LLC, a Colorado-based supplier of hemp-based CBD products free of tetrahydrocannabinol.
In April 2020, Perrigo received approval from the FDA to sell OTC diclofenac sodium topical gel 1%, the store brand equivalent to Voltaren gel, which provides temporary relief of arthritis pain.
www.perrigo.com
Sales: $926 million
Corporate sales: $5.0 billion.
Key Personnel
Rolf A. Classon, chairman; Murray S. Kessler, president and chief executive officer; Svend Andersen, EVP and president, Consumer Self-Care International; Richard S. Sorota, EVP and president, Consumer Self-Care Americas; James E. Dillard III, EXP and chief scientific officer; Grainne Quinn, EVP and chief medical officer; Ronald C. Janish, chief transformation officer
Major Products
Skin care, personal care and oral care products: ScarAway, Plackers, Rembrandt, Steripod, Firefly, Reach, Dr. Fresh, Aco, Biodermal, Canoderm, Dermalex, Lactacyd, Wartner, Jungle Formula, Paraniz, Pencivir
New Products
Steripod toothbrush accessories (acquisition), Emolium, Iwostin and Loxon skin care (acquisition).
Perrigo has acquired Steripod, which makes toothbrush protectors that guard toothbrushes from airborne contaminants, such as dirt, hair or debris, during travel and when staying home.
For example, in February 2020, Perrigo acquired the oral care assets of High Ridge Brands for $113 million in cash. In June 2020 it agreed to sell its UK-based Rosemont Pharmaceuticals business to a private equity firm.
Two months later, in August, it acquired three Eastern European OTC skin care and hair loss treatment brands (Emolium, Iwostin and Loxon) from Sanofi, which together generation sales of about $23 million a year.
The company continued to reshape its business in 2021. In May, it reached a definitive agreement to sell its Mexico and Brazil-based over-the-counter (OTC) businesses to Advent International. Last month, the company completed the sale of its generic Rx pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion.
“Closing this transaction was another important milestone for Perrigo’s transformation. We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality—to make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company’s future,” Perrigo CEO and President Murray S. Kessler, said when the Altaris deal was complete.
While legally based in Ireland, Perrigo building a new North American corporate headquarters in Grand Rapids, MI, specifically at Michigan State University’s Grand Rapids Innovation Park. The new HQ will augment its existing and storied presence in west Michigan, which was established in 1887 and currently includes operations in Allegan and Holland, too.
Like other personal care makers, Perrigo has some interest in CBD; it has formed a strategic investment in and long-term supply agreement with Kazmira LLC, a Colorado-based supplier of hemp-based CBD products free of tetrahydrocannabinol.
In April 2020, Perrigo received approval from the FDA to sell OTC diclofenac sodium topical gel 1%, the store brand equivalent to Voltaren gel, which provides temporary relief of arthritis pain.
